List of Excipients in Branded Drug COMTAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	COMTAN	entacapone	0078-0327	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	COMTAN	entacapone	0078-0327	CROSCARMELLOSE SODIUM
Novartis Pharmaceuticals Corporation	COMTAN	entacapone	0078-0327	FERRIC OXIDE RED
Novartis Pharmaceuticals Corporation	COMTAN	entacapone	0078-0327	FERRIC OXIDE YELLOW
Novartis Pharmaceuticals Corporation	COMTAN	entacapone	0078-0327	GLYCERIN
Novartis Pharmaceuticals Corporation	COMTAN	entacapone	0078-0327	HYDROGENATED COTTONSEED OIL
Novartis Pharmaceuticals Corporation	COMTAN	entacapone	0078-0327	HYPROMELLOSE

Comtan Excipient Strategy and Commercial Opportunities for Entacapone Tablets

Last updated: August 17, 2026

Comtan is the originator brand for entacapone, a 200 mg oral catechol-O-methyltransferase inhibitor used with levodopa/carbidopa in Parkinson's disease. Its commercial opportunity is now primarily generic and formulation-driven. The active ingredient is off-patent in the United States, no biosimilar pathway applies, and the main barriers are bioequivalence, dissolution control, tablet robustness, color and coating replication, and reliable low-cost manufacturing.

The strongest development strategy is a conventional immediate-release tablet using excipients that improve wetting, disintegration, manufacturability, and dose uniformity without creating unnecessary formulation distinctiveness. Higher-value opportunities include orally disintegrating tablets, fixed-dose levodopa combinations, multiparticulate products, and formulations designed to reduce food-related variability or improve adherence.

What is Comtan and how is entacapone used?

Comtan contains entacapone, a reversible peripheral COMT inhibitor. It is administered with each levodopa/carbidopa dose to prolong levodopa exposure and reduce end-of-dose "wearing-off" in patients with Parkinson's disease.

Attribute	Comtan
Active ingredient	Entacapone
Strength	200 mg
Dosage form	Immediate-release film-coated tablet
Originator	Novartis
FDA approval	1999, NDA 020796
Therapeutic category	Adjunctive treatment for Parkinson's disease
Administration	With levodopa/carbidopa
Regulatory pathway	Small-molecule NDA/ANDA
Biosimilar exposure	None
Primary commercial competitors	Generic entacapone tablets; Stalevo and generic carbidopa/levodopa/entacapone products

Entacapone is not a replacement for levodopa therapy. It is used as an adjunct and therefore depends commercially on the continuing use of levodopa/carbidopa products.

The Comtan label identifies a 200 mg tablet with an immediate-release design and a colored film coating. The product's inactive ingredients include conventional tablet fillers, binders, disintegrants, lubricants, coating agents, and colorants. Exact excipient composition should be confirmed against the applicable FDA label and current product listing before a formulation is selected.[1]

What excipient properties matter most for entacapone tablets?

Entacapone presents a conventional but meaningful formulation challenge because dissolution performance can affect exposure. The molecule has limited aqueous solubility and pH-dependent ionization. A generic product therefore needs consistent particle wetting, rapid tablet breakup, and reproducible dissolution across physiologic pH conditions.

Solubility and dissolution

The formulation should prioritize:

• Rapid liquid penetration into the tablet.
• Efficient disintegration after compression.
• Adequate drug deagglomeration.
• Controlled hydrophobic lubrication.
• Robust dissolution after storage.
• Limited sensitivity to manufacturing-scale changes.

Potential excipient classes include:

Formulation function	Candidate excipient classes	Commercial rationale
Diluent	Microcrystalline cellulose, mannitol, lactose, dibasic calcium phosphate	Controls tablet size, flow, compressibility, and cost
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Wetting aid	Surfactant or hydrophilic polymer at low concentration	Can improve dissolution of poorly wetting drug particles
Lubricant	Magnesium stearate, sodium stearyl fumarate, glyceryl behenate	Controls ejection and tooling performance
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxides	Protects the tablet and supports brand differentiation

The commercial target is not the maximum number of excipients. It is a formulation with sufficient dissolution margin to withstand normal variation in particle size, compression force, lubricant blending, humidity, and coating operations.

Particle-size control

Entacapone particle size can affect blend uniformity, dissolution, and compressibility. A milled active may improve dissolution but can increase cohesion, electrostatic charging, and segregation. A particle engineering program should compare:

1. Unmilled API.
2. Controlled milling.
3. Micronized API.
4. API premixed with a hydrophilic carrier.
5. Granulated API with a wetting or disintegrating excipient.

Particle-size specifications should be linked to dissolution and process capability rather than selected only from laboratory convenience.

What was the Comtan formulation strategy?

Comtan uses a conventional immediate-release film-coated tablet. Its formulation strategy emphasizes patient identification, dose-unit integrity, manufacturability, and a distinctive colored appearance rather than extended release.

The reference product's excipient system is commercially relevant for three reasons:

1. It establishes the benchmark for tablet disintegration and dissolution.
2. It defines the likely source of qualitative and quantitative formulation differences for an ANDA applicant.
3. It creates opportunities for a generic manufacturer to simplify the formula while preserving bioequivalence.

A generic developer does not need to copy every excipient quantitatively. The product must meet applicable pharmaceutical equivalence, bioequivalence, quality, and labeling requirements. The excipient selection should be justified by comparative dissolution, stability, impurity control, and process validation.

Which excipient combinations are commercially attractive?

Immediate-release conventional tablet

The lowest-risk formulation uses a direct-compression or dry-granulation platform with:

• A compressible diluent such as microcrystalline cellulose or mannitol.
• Crospovidone or croscarmellose sodium as the principal disintegrant.
• Povidone or copovidone if granulation is needed.
• Low-level colloidal silicon dioxide for flow.
• Magnesium stearate or sodium stearyl fumarate for lubrication.
• A conventional hypromellose or polyvinyl alcohol film coat.

This approach supports low manufacturing cost and a straightforward ANDA pathway. Its disadvantages are limited product differentiation and possible price erosion once several suppliers enter.

Mannitol-based tablet

Mannitol can support a hard, low-moisture tablet with a favorable mouthfeel and a relatively clean excipient profile. It is attractive for direct compression and orally disintegrating formats. The risks are higher raw-material cost than some lactose or starch systems and potential sensitivity to compaction conditions.

Lactose-containing tablet

Lactose may reduce material cost and improve powder handling in selected processes. It requires compatibility assessment because reducing sugars can react with susceptible drug molecules or formulation components. The final choice should be supported by forced-degradation and long-term stability data.

Sodium stearyl fumarate lubrication

Sodium stearyl fumarate can reduce the dissolution penalty associated with over-lubrication compared with magnesium stearate in some formulations. It may be useful where entacapone dissolution is close to the lower specification limit. The tradeoff is higher cost and less universal manufacturing familiarity.

Orally disintegrating tablet

An orally disintegrating entacapone product could target patients with dysphagia, motor impairment, or difficulty taking tablets during "off" episodes. The most suitable platforms are mannitol-based direct compression, co-processed excipient systems, or taste-masked granules.

The product must address:

• Entacapone taste and mouthfeel.
• Dose loading at 200 mg.
• Mechanical strength during packaging.
• Moisture protection.
• Rapid in vitro disintegration.
• Patient acceptability.
• Stability of the active and color system.

An orally disintegrating tablet would be a new dosage form rather than a simple generic substitution. It could require a 505(b)(2) or other regulatory strategy depending on the proposed product and FDA's determination.

What formulation patents protect Comtan?

The principal commercial protection for Comtan was associated with entacapone's active ingredient, pharmaceutical use, and branded product development. The key composition-of-matter and early regulatory exclusivity periods have expired or are no longer the primary commercial barrier in the United States.

The current opportunity is therefore not based on a surviving broad monopoly over conventional entacapone tablets. It is based on:

• Product quality.
• ANDA approval timing.
• Manufacturing cost.
• Supply reliability.
• Device or dosage-form differentiation.
• Fixed-dose combinations.
• Geographic expansion.
• Contract manufacturing and licensing.

Any applicant evaluating a specific product should conduct a current Orange Book and patent-family review for the relevant jurisdiction, product presentation, and proposed indication. Patent risk can differ between a conventional entacapone tablet, an orally disintegrating tablet, a fixed-dose combination, and a modified-release product.

Method-of-use patents

Method-of-use protection may historically have covered the use of entacapone with levodopa and dopa-decarboxylase inhibitors. Such protection is less commercially significant after expiration and in the presence of approved generic labeling. Skinny-label strategies can still be relevant if an unexpired method claim covers a non-core indication or dosing instruction, but the practical value depends on the current Orange Book listing and the proposed label.

Formulation patents

A new excipient system could support patent claims if it produces a technically meaningful result, such as:

• Improved dissolution under low-pH conditions.
• Reduced food effect.
• Improved stability against oxidation or hydrolysis.
• A defined particle-size distribution.
• A novel solid form or dispersion.
• Improved tablet disintegration at high drug loading.
• A specific fixed-dose combination with improved dose uniformity.

Routine substitution of one diluent or disintegrant for another usually has limited patent strength unless the data show an unexpected technical effect.

When does Comtan lose exclusivity and what is the generic outlook?

Comtan's US exclusivity is effectively a generic-market issue rather than an originator-exclusivity issue. Entacapone tablets have been available from generic manufacturers, and the originator brand does not retain the type of active patent position associated with a recently launched specialty medicine.

Exclusivity issue	Commercial status
New chemical entity exclusivity	Expired
Core composition patent	Expired or no longer commercially controlling in the US
Conventional tablet generic entry	Established
Biosimilar pathway	Not applicable
ANDA pathway	Available
Primary remaining barrier	Bioequivalence, CMC, supply, and pricing

Paragraph IV challenges

A Paragraph IV challenge is most relevant when an applicant seeks approval before expiration of a listed patent. For a mature entacapone tablet product, the commercial importance of a new Paragraph IV filing is likely limited unless a currently listed patent covers a specific formulation, use, or combination.

The central due-diligence documents are:

• FDA Orange Book patent listings.
• Approved NDA and ANDA records.
• Patent expiration and pediatric-extension data.
• Federal court docket searches.
• Any settlement or licensing agreements involving the relevant applicant.

Litigation and settlement exposure

The expected litigation profile is lower than for a recently launched branded drug because conventional entacapone tablets already face generic competition. Litigation risk remains possible for a differentiated product, especially a fixed-dose combination or a new dosage form. A settlement could affect launch timing, but no broad conclusion should be drawn from historical entacapone litigation without a current docket and agreement review.

What is the FDA and Orange Book status of Comtan?

Comtan was approved by FDA under NDA 020796. The FDA-approved product is an immediate-release 200 mg tablet. Generic entacapone products are approved through ANDAs and are evaluated against the reference-listed drug for pharmaceutical equivalence and bioequivalence.[1,2]

The Orange Book is relevant for:

• Identifying the reference-listed drug.
• Reviewing current patent listings.
• Confirming therapeutic equivalence codes.
• Checking whether a formulation or method-of-use patent remains listed.
• Assessing whether an ANDA applicant could receive approval without a patent certification issue.

The regulatory status of a specific manufacturer should be verified against the current FDA Drugs@FDA and Orange Book records because marketing status, applicant ownership, discontinued-product designations, and patent listings can change.[2,3]

How strong is the entacapone patent estate?

The patent estate for a conventional entacapone tablet is weak from an exclusivity perspective because the active pharmaceutical ingredient and original product have been commercially available for many years.

Patent-estate dimension	Strength
Core molecule	Low remaining exclusivity value
Conventional immediate-release tablet	Low
Basic adjunctive use with levodopa	Low
New solid form	Potentially moderate, claim-dependent
Orally disintegrating tablet	Potentially moderate
Fixed-dose combination	Potentially moderate to strong if technically differentiated
Manufacturing process	Variable; usually narrow
Device-enabled delivery	Potentially moderate, but limited relevance to Comtan's current tablet market

The strongest new intellectual-property position would likely require a differentiated dosage form or combination with measurable clinical, pharmacokinetic, adherence, or manufacturing advantages.

What commercial opportunities exist for entacapone?

Low-cost generic supply

The largest practical opportunity is a dependable generic supply business. Entacapone is suitable for a manufacturer with:

• Existing oral-solid-dose capacity.
• Access to qualified API.
• Low-cost coating and packaging operations.
• Strong dissolution and stability laboratories.
• Experience with ANDA lifecycle management.

Price competition is likely, so manufacturing efficiency and supply continuity matter more than a marginal excipient distinction.

Fixed-dose combinations

The most commercially attractive product strategy is a fixed-dose combination containing carbidopa, levodopa, and entacapone. Stalevo established the commercial model for this combination. A generic combination can improve pill burden and adherence but has more demanding development requirements because it must control three active ingredients with different dose ratios and stability profiles.

Key technical issues include:

• Segregation among active ingredients.
• Dose uniformity across strengths.
• Dissolution of each active.
• Impurity interactions.
• Large tablet size.
• Multiple strength presentations.
• Bioequivalence across the full product range.

Orally disintegrating and sprinkle products

Patients with Parkinson's disease can experience swallowing difficulty and fluctuating motor function. An orally disintegrating product could support adherence and product differentiation. A sprinkle formulation could target patients requiring administration through soft food, but taste masking and dose uniformity would be central development risks.

Geographic expansion

Entacapone has broader potential in markets where:

• Generic Parkinson's treatment is expanding.
• Combination products are underpenetrated.
• Local manufacturing is favored.
• Brand pricing remains high relative to generic cost.
• Regulatory agencies accept established reference products or abridged applications.

Commercial value will vary significantly by country because patent status, reference-product availability, reimbursement, and substitution rules are local.

Contract manufacturing and licensing

A formulation owner could license:

• An optimized immediate-release formula.
• A fixed-dose combination.
• A regional registration package.
• An API and finished-dose supply arrangement.
• A differentiated ODT or multiparticulate technology.

The most bankable licensing structure would link territory rights to regulatory milestones, minimum supply commitments, pharmacovigilance responsibilities, and demonstrated manufacturing scale.

How does Comtan compare with Stalevo and generic combinations?

Product	Active ingredients	Main commercial position	Formulation opportunity
Comtan	Entacapone	Adjunct tablet used with levodopa/carbidopa	Low-cost generic, ODT, adherence-oriented formats
Stalevo	Carbidopa, levodopa, entacapone	Fixed-dose combination	Generic substitution, strength expansion, tablet-size reduction
Generic entacapone	Entacapone	Direct substitution for Comtan	Cost, supply reliability, therapeutic equivalence
Generic carbidopa/levodopa/entacapone	Three active ingredients	Reduced pill burden	Dose-ratio coverage, stability, manufacturing scale

Comtan has the simpler development path. Stalevo-type products have greater commercial differentiation but materially greater formulation and regulatory complexity.

What generic launch risks exist for entacapone?

The principal risks are:

1. Dissolution failure caused by poor wetting or over-lubrication.
2. Stability problems linked to moisture, light, or excipient compatibility.
3. Color and coating variability affecting product identification.
4. Scale-up changes that alter hardness or disintegration.
5. API particle-size drift between suppliers.
6. Weak supply economics after multiple generic launches.
7. Limited reimbursement differentiation.
8. Inadequate demand forecasting in a mature Parkinson's market.
9. Combination-product complexity for carbidopa/levodopa/entacapone.
10. Regulatory delay caused by incomplete CMC comparability.

A formulation with a generous dissolution margin and simple manufacturing process is usually more valuable than a highly engineered formula with narrow process tolerances.

Key Takeaways

• Comtan is a mature entacapone product with limited remaining US exclusivity value.
• The main opportunity is generic supply, not recovery of originator-like patent pricing.
• Conventional immediate-release tablets should use a simple excipient system optimized for wetting, disintegration, compression, and dissolution.
• Crospovidone, croscarmellose sodium, mannitol, microcrystalline cellulose, povidone, and low-impact lubrication systems are practical development options.
• Orally disintegrating tablets and fixed-dose carbidopa/levodopa/entacapone products offer greater differentiation but carry higher development risk.
• New patent value would depend on a demonstrated technical effect, not routine excipient substitution.
• Entacapone has no biosimilar risk because it is a small-molecule drug.
• The commercial success of a new product will depend on ANDA execution, API consistency, manufacturing cost, supply reliability, and market access.

FAQs

Can entacapone be formulated as an orally disintegrating tablet?

Yes. A mannitol-based direct-compression system with a high-efficiency disintegrant is a plausible platform. Taste masking, mechanical strength, moisture protection, and dose loading are the main technical issues.

Which excipient is most important for entacapone dissolution?

No single excipient determines performance. The most important variables are API particle size, wetting, disintegrant efficiency, lubricant level, compression force, and dissolution testing across relevant pH conditions.

Does entacapone require a biosimilar application?

No. Entacapone is a chemically synthesized small molecule. A conventional generic product is generally pursued through an ANDA or a jurisdiction-specific abridged application.

Can a new entacapone formulation receive patent protection?

Yes, but routine excipient changes are unlikely to provide strong protection. Patentability is stronger where the formulation produces an unexpected dissolution, stability, pharmacokinetic, adherence, or manufacturing benefit.

Is a fixed-dose entacapone combination more valuable than a standalone tablet?

Potentially. A carbidopa/levodopa/entacapone product can reduce pill burden and create greater product differentiation, but it requires more complex formulation, bioequivalence, stability, and manufacturing work.

References

1. Novartis Pharmaceuticals Corporation. (1999). Comtan (entacapone) tablets prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-overview

4. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances

5. European Medicines Agency. (n.d.). Stalevo: EPAR product information. https://www.ema.europa.eu/en/medicines/human/EPAR/stalevo